Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University · 2001
[Efficacy and safety of low dose amiodarone for paroxysmal atrial fibrillation in the aged patients with no-valvular heart diseases].
Аннотация на английскомСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen H, Yang Y
Аннотация
OBJECTIVE: To study the efficacy and safety of low-dose amiodarone (AD) for paroxysmal atrial fibrillation in the aged patients with no-valvular heart diseases.
METHOD: 40 inpatients were treated with load-dose AD (600 mg.d-1) for 6 days and then low maintenance dose of 50 mg or 100 mg daily. Clinical efficacy was evaluated with 24 h dynamic electrocardiogram.
RESULTS: AD maintained efficaciously sinus rhythm about 90.0% (36/40) during 6 months, about 83.3% (25/30) during 12 months, about 72.7% (16/22) during 24 months. Only 2 patients were stopped oral AD because sinus bradycardia(< or = 45 bpm) occurred.
CONCLUSION: Low dose AD (50-100 mg.d-1) is a safe and efficient maintenance of sinus rhythm in aged patients with no-valvular heart diseases and paroxysmal atrial fibrillation.
METHOD: 40 inpatients were treated with load-dose AD (600 mg.d-1) for 6 days and then low maintenance dose of 50 mg or 100 mg daily. Clinical efficacy was evaluated with 24 h dynamic electrocardiogram.
RESULTS: AD maintained efficaciously sinus rhythm about 90.0% (36/40) during 6 months, about 83.3% (25/30) during 12 months, about 72.7% (16/22) during 24 months. Only 2 patients were stopped oral AD because sinus bradycardia(< or = 45 bpm) occurred.
CONCLUSION: Low dose AD (50-100 mg.d-1) is a safe and efficient maintenance of sinus rhythm in aged patients with no-valvular heart diseases and paroxysmal atrial fibrillation.